ZEALAND PHARMA A/S (22Z.DE) Forecast, Price Target & Analyst Ratings

FRA:22Z • DK0060257814

Current stock price

35.98 EUR
+0.49 (+1.38%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZEALAND PHARMA A/S (22Z.DE).

Forecast Snapshot

Consensus Price Target

Price Target
€94.30
+ 162.10% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-DKK9.12
Revenue Estimate
32.81M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
81.67%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€94.30
Upside
+ 162.10%
From current price of €35.98 to mean target of €94.30, Based on 24 analyst forecasts
Low
€54.10
Median
€88.79
High
€134.99

Price Target Revisions

1 Month
-2.04%
3 Months
-7.48%

Price Target Summary

24 Wall Street analysts provided a forecast for the next 12 months for 22Z.DE. The average price target is 94.3 EUR. This implies a price increase of 162.1% is expected in the next year compared to the current price of 35.98.
The average price target has been revised downward by 7.48% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

22Z Current Analyst Rating22Z Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

22Z Historical Analyst Ratings22Z Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
81.67%
22Z.DE was analyzed by 24 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about 22Z.DE.
In the previous month the buy percentage consensus was at a similar level.
22Z.DE was analyzed by 24 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-DKK9.12
Revenue Estimate
32.81M
Revenue Q2Q
305.46%
EPS Q2Q
-91.97%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
255.43%
Revenue (3 Months)
261.42%
EPS (1 Month)
-4.62%
EPS (3 Months)
-0.98%

Next Earnings Summary

22Z.DE is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -9.12 EUR and the consensus revenue estimate is 32.81M EUR.
The next earnings revenue estimate has been revised upward by 261.42% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
22Z.DE revenue by date.22Z.DE revenue by date.
342.788M
229.65%		62.691M
-81.71%		9.215B
14,598.86%		4.817B
-47.73%		3.957B
-17.85%		971M
-75.46%		2.44B
151.29%		2.367B
-2.99%		4.302B
81.75%		5.833B
35.59%		9.026B
54.74%
EBITDA
YoY % growth
22Z.DE ebitda by date.22Z.DE ebitda by date.
-536.152M
18.51%		-1.243B
-131.88%		7.141B
674.39%		1.532B
-78.55%		-1.437B
-193.82%		-1.676B
-16.62%		-1.321B
21.19%		-115.657M
91.25%		N/AN/AN/A
EBIT
YoY % growth
22Z.DE ebit by date.22Z.DE ebit by date.
-561.238M
27.66%		-1.269B
-126.12%		7.114B
660.53%		1.028B
-85.55%		-361.877M
-135.20%		-3.863B
-967.61%		-1.524B
60.57%		-1.977B
-29.76%		-233.07M
88.21%		1.069B
558.66%		3.962B
270.63%
Operating Margin
22Z.DE operating margin by date.22Z.DE operating margin by date.
-163.73%-2,024.33%77.20%21.34%-9.15%-397.88%-62.44%-83.52%-5.42%18.33%43.90%
EPS
YoY % growth
22Z.DE eps by date.22Z.DE eps by date.
-12.44
52.19%		-16.27
-30.79%		96.00
690.04%		9.67
-89.93%		-8.97
-192.78%		-34.13
-280.38%		-15.42
54.83%		2.01
113.03%		18.79
835.35%		37.38
98.92%		57.05
52.63%

All data in DKK

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-9.12
-91.97%		-4.09
-103.80%		5.27
191.71%		3.90
451.49%
Revenue
Q2Q % growth		32.81M
305.46%		875.26M
-90.37%		1.288B
2,498.40%		5.328B
7,616.15%
EBITDA
Q2Q % growth		-645.423M
-70.07%		77.871M
-99.09%		N/AN/A
EBIT
Q2Q % growth		-681.752M
-76.87%		56.021M
-99.34%		1.7B
468.51%		1.656B
334.21%

All data in DKK

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

22Z.DE Yearly Revenue VS Estimates22Z.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
22Z.DE Yearly EPS VS Estimates22Z.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 40 60 80

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-33.05%
EPS Next 5 Year
-53.85%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-53.14%
Revenue Next 5 Year
-24.16%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-30.81%
EBIT Next 5 Year
-15.06%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ZEALAND PHARMA A/S / 22Z.DE Forecast FAQ

What is the average price target for ZEALAND PHARMA A/S (22Z.DE) stock?

24 analysts have analysed 22Z.DE and the average price target is 94.3 EUR. This implies a price increase of 162.1% is expected in the next year compared to the current price of 35.98.

What is the next earnings date for 22Z stock?

ZEALAND PHARMA A/S (22Z.DE) will report earnings on 2026-05-07.

Can you provide the consensus estimates for ZEALAND PHARMA A/S next earnings?

The consensus EPS estimate for the next earnings of ZEALAND PHARMA A/S (22Z.DE) is -9.12 EUR and the consensus revenue estimate is 32.81M EUR.

What is the expected long term growth rate for 22Z stock?

The expected long term growth rate for ZEALAND PHARMA A/S (22Z.DE) is -53.14%.